Controversy heats up over amlodipine issue
Published: 2004-06-04 06:59:00
Updated: 2004-06-04 06:59:00
A controversy is brewing over the approval of Pfizer's amlodipine generic versions after some media's report on the Korea Food and Drug Administration's intention to permit the omission of clinical trials on latecomer's me-too products.
In response, the KFDA clarified recently that it did not ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
